Eco Animal Health Group Plc
ECO Animal Health Group plc is a leader in the development, registration and marketing of pharmaceutical products for global animal health markets. Our products for these growth markets promote well-being in animals. Our financial goals are achieved through the careful and responsible application of science to generate value for our shareholders.
ECO Animal Health forms North America distribution JV
ECO Animal Health Group PLC (AIM: EAH) said ECO Animal Health Ltd has formed a joint venture with Pharmgate LLC of Ramsey, New Jersey, aimed at distributing the partners’ veterinary products in the North American livestock and poultry markets.
Pharmgate is the wholly-owned US subsidiary of Jinhe Biotechnology Ltd of China.
The venture is called Pharmgate Animal Health LLC and will benefit from the manufacturing and product development experience of its owners to bring to market their ranges of extensively used medicated feed additives and new therapeutic compounds for livestock and poultry, backed by a specialist sales and technical team.
ECO Animal Health Group CEO Marc Loomes said: "This is an important step in the global commercialisation of Aivlosin, our novel antibiotic for the treatment of enteric and respiratory disease in swine and poultry. Pre-approval studies in the US market have shown similar performance of Aivlosin to that seen in markets where the product is already being successfully sold, including Europe, Central and Latin America, China, Japan, South East Asia and Africa.”
Pharmgate general manager Colin Gray commented: “Our FDA-approved (Food and Drug Administration) manufacturing facilities in China meet the highest international quality, safety and environmental standards and are well-known to the industry. We look forward to satisfying our customers' requirements for a streamlined, no-nonsense source of key animal health products.”
ECO Animal Health Group develops, registers and markets pharmaceutical products for global animal health markets. Its products for these growth markets promote well-being in animals and include the novel macrolide antibiotic, Aivlosin, as well as a range of generic therapeutic products.
Jinhe Biotechnology Co produces chlortetracycline feed grade, chlortetracycline hydrochloride, salinomycin and other animal health compounds. The company has marketing or supply approvals for these products in most major markets throughout the world.
Other Eco Animal Health Group Plc news
-
26/07/10 ECO Animal Health Group’s Chinese Aivlosin factory gets US FDA approval
-
10/03/10 Eco Animal Health Group: moves into US and China could be transformational
-
02/02/10 ECO Animal Health wins marketing approval in Mexico for dog’s heartworm treatment
Investors interested in Eco Animal Health Group Plc recently viewed
-
Access Pharmaceuticals (OTCBB: ACCP)
-
Alliance Pharma (AIM: APH)
-
Amphion Innovations (LON: AMP)
-
Asterand (LSE: ATD)
-
Biocompatibles (LSE: BII)
-
BioNeutral Group (OTCBB: BONU)
-
Bionomics (ASX: BNO)
-
Circadian Technologies Limited (ASX: CIR)
-
CogState (ASX: CGS)
-
e-Therapeutics plc (AIM: ETX)
-
Epistem (AIM: EHP)
-
ImmuPharma PLC (AIM: IMM)
-
Lipoxen (AIM: LPX)
-
Medical Australia Limited (ASX: MLA)
-
Oxford Nutrascience (AIM: ONG)
-
Renovo Group Plc (LSE: RNVO)
-
Rexahn Pharmaceuticals (AMEX: RNN)
-
Silence Therapeutics (AIM: SLN)
-
Starpharma (ASX: SPL)
-
Stirling Products Limited (ASX: STI)










